Contrastingly, in clinical trials, GLP-1 agonists lower weight less dramatically. Regardless, their use could be beneficial as obesity increases surgical morbidity and operative costs (time) in those undergoing benign hysterectomy with BMI over 40 kg/m2 [2]. This evidence concerns the gene GLP1R and obesity disorder.